摘要
上尿路上皮癌(UTUC)患者手术后复发率高且预后差。既往临床研究结果多数基于回顾性研究,对于术后辅助化疗是否可以改善患者生存尚有争论。近期临床试验结果支持辅助化疗可改善局部晚期UTUC患者的无瘤生存,含铂类药物方案是术后辅助化疗的标准方案。目前尚缺乏术前新辅助化疗与术后辅助化疗对照的临床研究结果,随着靶向治疗及免疫治疗进展,新药联合辅助治疗方案可能会进一步改善UTUC患者生存。
Upper tract urothelial carcinoma(UTUC)patients have high recurrent rate and poor survival.Most of the previous studies of adjuvant chemotherapy in UTUC were retrospective and the results were controversial.Recent clinical trials support that adjuvant chemotherapy can improve disease-free survival of patients with locally advanced UTUC and platinum based regimens are standard adjuvant treatment.Currently the clinical trials results about effect comparison between adjuvant treatment and neoadjuvant treatment are limited.With the development of targeted therapy and immunotherapy,combinations with novel agents in the adjuvant setting might further improve the prognosis for locally advanced UTUC.
作者
王墨培
马力文
Wang Mopei;Ma Liwen(Department of Tumor Chemotherapy and Radiation Sickness,Peking University Third Hospital,Beijing 100191,China)
出处
《国际肿瘤学杂志》
CAS
2020年第7期436-439,共4页
Journal of International Oncology
关键词
泌尿系肿瘤
化学疗法
辅助
Urologic neoplasms
Chemotherapy
adjuvant
